Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
PRFX 
Painreform Ltd (PRFX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/07/2026: PRFX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.84% | Avg. Invested days 7 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/07/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.87M USD | Price to earnings Ratio 0.03 | 1Y Target Price 12 |
Price to earnings Ratio 0.03 | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.55 | 52 Weeks Range 0.61 - 5.47 | Updated Date 11/14/2025 |
52 Weeks Range 0.61 - 5.47 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 29.9 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.19% | Return on Equity (TTM) -127.65% |
Valuation
Trailing PE 0.03 | Forward PE - | Enterprise Value -770358 | Price to Sales(TTM) - |
Enterprise Value -770358 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.32 | Shares Outstanding 2013141 | Shares Floating 1834374 |
Shares Outstanding 2013141 | Shares Floating 1834374 | ||
Percent Insiders 9.4 | Percent Institutions 2.45 |
Upturn AI SWOT
Painreform Ltd
Company Overview
History and Background
PainReform Ltd. (NASDAQ: PRFM) is a biotechnology company focused on developing and commercializing novel reformulations of existing drug products. The company was founded in 2001 and is headquartered in Ramat Gan, Israel. Its primary focus is on addressing unmet needs in pain management.
Core Business Areas
- Pain Management Therapeutics: Developing and commercializing innovative drug formulations for the treatment of acute and chronic pain. This includes proprietary technologies aimed at improving drug delivery and reducing side effects.
Leadership and Structure
Information on the specific leadership team and detailed organizational structure for PainReform Ltd. is not readily available in public domain financial reports. Publicly traded companies typically have a Board of Directors and executive management team responsible for strategic direction and operations.
Top Products and Market Share
Key Offerings
- PRX-100 (formerly known as ADX-100): A proprietary, extended-release, localized anesthetic drug candidate designed for postsurgical pain management. It aims to provide prolonged pain relief at the surgical site, potentially reducing the need for systemic opioids. Market share data is not publicly available as it is a drug candidate still in development. Key competitors in the postsurgical pain management market include pharmaceutical companies with opioid-based analgesics, non-opioid pain relievers, and other localized anesthetic formulations. For example, companies like Pfizer (with Lyrica/Celebrex), J&J (with various pain management products), and numerous smaller biotech firms are active in this space.
Market Dynamics
Industry Overview
The pain management market is a significant and growing sector within the pharmaceutical and biotechnology industries, driven by an aging population, an increase in chronic diseases, and a growing awareness of the impact of poorly managed pain. However, there is also a strong push to address the opioid crisis, leading to increased demand for non-addictive and localized pain management solutions.
Positioning
PainReform Ltd. is positioning itself to address the unmet needs in pain management, particularly in the postsurgical setting, by developing non-opioid, localized, and extended-release anesthetic solutions. Its competitive advantage lies in its proprietary technology for drug reformulation and extended release, aiming to offer a safer and more effective alternative to current treatments.
Total Addressable Market (TAM)
The global pain management market is substantial, estimated to be in the tens of billions of dollars annually, with the postsurgical pain management segment representing a significant portion of this. PainReform Ltd. is targeting a niche within this TAM with its specialized drug candidate, aiming to capture a share of the market seeking advanced pain relief solutions.
Upturn SWOT Analysis
Strengths
- Proprietary extended-release drug delivery technology.
- Focus on a significant unmet need in postsurgical pain management.
- Potential for a non-opioid, localized treatment option.
Weaknesses
- Reliance on a single primary drug candidate (PRX-100) for commercial success.
- As a development-stage company, it lacks current revenue streams from commercialized products.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Growing demand for non-opioid pain management solutions.
- Potential for partnerships or licensing agreements with larger pharmaceutical companies.
- Expansion of indications beyond postsurgical pain.
Threats
- Regulatory hurdles and lengthy approval processes for new drugs.
- Competition from established pain management therapies and new entrants.
- Potential for clinical trial failures or unexpected side effects.
- Changes in healthcare reimbursement policies.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Johnson & Johnson (JNJ)
- AbbVie Inc. (ABBV)
- AstraZeneca PLC (AZN)
Competitive Landscape
PainReform Ltd. operates in a highly competitive pain management market dominated by large pharmaceutical companies with established product portfolios and significant R&D budgets. Its advantage lies in its specialized focus on localized, extended-release anesthetic for postsurgical pain, potentially offering a differentiated solution. However, it faces challenges in competing with the market penetration, brand recognition, and extensive distribution networks of larger players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for PainReform Ltd. has been in terms of advancing its drug development pipeline and securing funding for R&D. Revenue growth is not applicable until product commercialization.
Future Projections: Future projections are highly speculative and dependent on the successful clinical development and regulatory approval of PRX-100. Analyst estimates, if available, would focus on potential market penetration and future revenue streams post-launch.
Recent Initiatives: Recent initiatives likely involve advancing PRX-100 through its clinical trial phases, seeking regulatory feedback, and exploring potential strategic partnerships or financing rounds.
Summary
PainReform Ltd. is a biotechnology company focused on innovative pain management solutions, particularly postsurgical pain with its PRX-100 candidate. Its proprietary technology offers a potential non-opioid alternative. However, the company faces significant risks associated with drug development, regulatory approvals, and intense competition from larger established players, making its future success heavily dependent on the clinical and commercial outcome of its lead product.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Financial Data Providers (e.g., Refinitiv, Bloomberg)
- Industry Research Reports
- Company Investor Relations Websites
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investing in biotechnology companies, especially development-stage ones, carries significant risks, including the potential loss of invested capital. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Painreform Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-01 | Interim CEO & Executive Chairman Dr. Ehud Geller Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2 | Website https://www.painreform.com |
Full time employees 2 | Website https://www.painreform.com | ||
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.